PG
GEVA

PEAK6 Group’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

PEAK6 Group’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-2,700
Closed -$263K – 5927
2015
Q1 		$263K Sell
2,700
-14,600
-84% -$1.55M ﹤0.01% 3182
2014
Q4 		$1.6M Sell
17,300
-36,900
-68% -$2.91M 0.01% 1540
2014
Q3 		$3.73M Sell
54,200
-122,900
-69% -$8.8M 0.03% 813
2014
Q2 		$18.6M Buy
177,100
+60,200
+51% +$5.12M 0.18% 100
2014
Q1 		$9.7M Buy
+116,900
New +$10.8M 0.08% 286

PEAK6 Group's GEVA Position: Q2 2015 in Review

PEAK6 Group sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 1,515 shares — an estimated $148K sold.

PEAK6 Group first reported a position in GEVA in Q1 2015 and held it in 1 quarter. The position peaked at $148K in Q1 2015. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • PEAK6 Group reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • PEAK6 Group sold 1,515 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $148K.
  • PEAK6 Group first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q1 2015 and held it in 1 quarter.
  • PEAK6 Group's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $148K in Q1 2015.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on PEAK6 Group's 13F filing for Q2 2015, filed 11 Aug 2015.